ReviewCritical care (London, England)2017
Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment.
Review in Critical care (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 287 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
287 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Global insights into MRSA bacteremia: a bibliometric analysis and future outlook.Frontiers in microbiology · 2024Pooled it
- Vancomycin, Daptomycin, Antistaphylococcal β-Lactam, and Trimethoprim-Sulfamethoxazole Monotherapy and Combination Therapy in the Management of Methicillin-ResistantFrontiers in pharmacology · 2022Pooled it
- Pooled it
- Evaluation of Daptomycin Use in Outpatients With Methicillin-SensitiveOpen forum infectious diseases · 2025Trial
- Development of a rapid diagnostic test for the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus: Cefinase disk direct (CDD) test.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Prevalence, Antimicrobial Resistance Profile, and Multidrug Resistance of Methicillin-ResistantHealth science reports · 2026Article
- Article
- Article
- Ceftaroline for Methicillin-Resistant Staphylococcus aureus Endovascular Infection.Infectious diseases and therapy · 2026Review
- Early cell-wall stress signatures enable 20-min ATR-FTIR discrimination of MRSA and MSSA.Scientific reports · 2026Article
- Characterization and antibacterial efficacy of the broad-host-range phage P108 against biofilm-forming and methicillin-resistant Staphylococcus aureus.Virus research · 2026Article
- mGem: Population genomics ofmBio · 2026Article
- In vitro antibacterial properties of selected medicinal plants used by traditional healers for gastrointestinal disorders in the Heban-Arsi and Kofale districts of Southern Ethiopia.BMC complementary medicine and therapies · 2026Article
- Advancements in CRISPR-Cas Systems for Genome Editing towards Eradication of Human Microbial Pathogens.Molecular biotechnology · 2026Review
- Virulence Phenotypes Differentiate Persistent vs. Resolving Isolates of HumanAntibiotics (Basel, Switzerland) · 2026Article
- Article
- Lactilactobacillus curvatus TH19-7: a broad-spectrum antimicrobial probiotic targeting skin pathogens and mitigating infection-associated dermal damage in vitro.Archives of microbiology · 2026Article
- The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies.Infectious diseases and therapy · 2026Review
- Toward precision risk stratification: predicting in-hospital death in sepsis patients with MRSA bacteremia.BMC infectious diseases · 2026Article
- Bacterial colonization of the respiratory tract in COVID-19 patients: potential source of bacterial infection.BMC infectious diseases · 2026Article
227 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) infection is still a major global healthcare problem. Of concern is S. aureus bacteremia, which exhibits high rates of morbidity and mortality and can cause metastatic or complicated infections such as infective endocarditis or sepsis. MRSA is responsible for most global S. aureus bacteremia cases, and compared with methicillin-sensitive S. aureus, MRSA infection is associated with poorer clinical outcomes. S. aureus virulence is affected by the unique combination of toxin and immune-modulatory gene products, which may differ by geographic location and healthcare- or community-associated acquisition. Management of S. aureus bacteremia involves timely identification of the infecting strain and source of infection, proper choice of antibiotic treatment, and robust prevention strategies. Resistance and nonsusceptibility to first-line antimicrobials combined with a lack of equally effective alternatives complicates MRSA bacteremia treatment. This review describes trends in epidemiology and factors that influence the incidence of MRSA bacteremia. Current and developing diagnostic tools, treatments, and prevention strategies are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.